CJC-1295 / Ipamorelin Research Blend
Research use only. Laboratory and investigational purposes — not for human or animal consumption.
Waitlist open · lot reserved · COA upon batch release
$70.00
FOR RESEARCH USE ONLY. Not for human consumption, medical use, or therapeutic application of any kind.
Join the inventory waitlist. This batch is not yet available to order. Review the lot specifications above, then get notified when inventory opens.
Request inventory alert
PayPal, Zelle, or cryptocurrency at checkout · Ships in 1–2 business days after payment
FOR RESEARCH USE ONLY — Molecular Research Profile
CJC-1295/Ipamorelin Research Blend — Molecular Research Profile
CJC-1295/Ipamorelin Research Blend is a two-component lyophilized preparation combining CJC-1295 (Modified GRF 1-29, a GHRH receptor agonist analog; ~3,364 Da) and Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂ pentapeptide ghrelin receptor agonist; 711.9 Da) — two structurally distinct peptides studied in vitro for growth hormone secretagogue receptor (GHS-R) and GHRH receptor signaling in cell-based assays.
Molecular Architecture — Per Component
- CJC-1295 structure
- Modified GRF 1-29 (GHRH 1-29 analog with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27); 29 residues; MW ~3,364 Da; no DAC modification in this blend form
- Ipamorelin sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (6 residues including Aib); MW 711.9 Da; selective GHS-R agonist scaffold derived from GHRP-6 class peptides
- Blend composition
- 5 mg CJC-1295 + 5 mg Ipamorelin per vial (10 mg total); co-lyophilized; each component ≥99% HPLC purity (individual chromatograms available in lot documentation)
Receptor Binding and Signaling Mechanics
CJC-1295 engages the GHRH receptor (GHRHR) with nanomolar affinity in radioligand displacement assays, activating adenylyl cyclase → cAMP → PKA signaling in pituitary-derived cell lines. Ipamorelin selectively activates the ghrelin receptor (GHS-R1a) with minimal reported off-target activity on cortisol and prolactin axes in published cell-based assays, engaging Gαq/11 → PLC → IP₃/DAG → Ca²⁺ mobilization and downstream ERK1/2 phosphorylation pathways.
Intracellular signaling cascade:
- CJC-1295: GHRHR → Gs → adenylyl cyclase → cAMP → PKA → CREB phosphorylation (pituitary cell-line assays)
- Ipamorelin: GHS-R1a → Gαq/11 → PLC → IP₃ → intracellular Ca²⁺ mobilization
- Ipamorelin: ERK1/2 Thr202/Tyr204 phosphorylation in GHS-R-expressing cell lines
- Blend note: GHRHR and GHS-R pathways can converge on shared downstream signaling nodes — individual-component controls required for attribution
In Vitro Research Profile
- CJC-1295 primary assay
- GHRHR cAMP accumulation assay (GloSensor or HTRF) in GHRHR-transfected HEK293 cells; concentration range 10⁻¹¹–10⁻⁷ M
- Ipamorelin primary assay
- GHS-R1a Ca²⁺ mobilization (FLIPR or Fura-2) in GHS-R-expressing cell lines; 10⁻¹⁰–10⁻⁷ M; compare vs. ghrelin reference agonist
- Ipamorelin secondary assay
- ERK1/2 phosphorylation by Western blot or HTRF; 15–30 min stimulation at 37°C
- Blend design note
- Component-resolved in vitro designs are commonly reported in dual-peptide signaling literature; GHRHR and GHS-R represent distinct receptor targets in cell-based assays.
- Known limitations
- In vitro receptor assays do not predict in vivo pharmacology; blend-mode pathway cross-talk requires component-resolved experimental design
Research Use Only — Regulatory Notice
All compounds on this page are sold exclusively for in vitro laboratory research. They are not approved by the FDA, DEA, or any regulatory agency for human or animal use, therapeutic application, clinical investigation, or consumption of any kind. Binding affinities, IC50/EC50 values, and signaling cascade descriptions referenced herein derive from published in vitro and cell-based literature and do not constitute efficacy or safety claims. Researchers are responsible for complying with all applicable institutional, local, and federal regulations governing the handling and use of research chemicals.
